Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06951880 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT06951880: Clinical Trial Phase 1 study, sponsored by AstraZeneca.
NCT06951880 is a Phase 1 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 160 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06951880, a Phase 1 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.
Primary Outcome
The safety and tolerability of AZD4916 following oral administration of single-ascending doses and multiple-ascending doses to healthy participants (including Japanese and Chinese) will be assessed.
Interventions
- OTHER Placebo
- DRUG AZD4916
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-07-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 1 |
What is known before NCT06951880 opens enrollment
NCT06951880 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06951880 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06951880 about?
NCT06951880 is a clinical study titled "A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers". The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.
What is the current status of trial NCT06951880?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-07-23. Estimated completion is 2027-10-25.
What interventions are being tested in trial NCT06951880?
The interventions under investigation include: Placebo (OTHER), AZD4916 (DRUG).
Who is sponsoring clinical trial NCT06951880?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06951880's enrollment target sits among peer trials
160 340th of 2000 higher than 1,655 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI